Video

Dr. Grünwald on depth of response and efficacy with pembrolizumab/lenvatinib in renal cell carcinoma

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

The phase 3 CLEAR trial showed that frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma.

In this video, Viktor Grünwald, MD, University Hospital Essen, Germany, discusses an analysis shared at the 2021 ASCO Annual Meeting which explored efficacy in the CLEAR trial according to selected subgroups, as well as the association between depth of response and overall survival. (J Clin Oncol 39, 2021 [suppl 15; abstr 4560])

Related Videos
Landon Trost, MD, answers a question during a video interview
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Related Content
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 3rd 2024

Ra223 plus SABR does not delay progression of oligometastatic HSPC

Benjamin P. Saylor
"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT
October 3rd 2024

MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT

Hannah Clarke
“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote.
Speaking of Urology: 2023 AUA Highlights
May 12th 2023

Speaking of Urology: 2023 AUA Highlights

Urology Times staff
Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.
Focal salvage HDR brachytherapy appears safe, efficacious in radiorecurrent prostate cancer
October 2nd 2024

Focal salvage HDR brachytherapy appears safe, efficacious in radiorecurrent prostate cancer

Hannah Clarke
The 3-year biochemical progression-free survival was 61%, and the 3-year radiographic progression-free survival was 67%.
BCR within 5 years is prognostic for metastasis, prostate cancer-specific mortality
October 1st 2024

BCR within 5 years is prognostic for metastasis, prostate cancer-specific mortality

Hannah Clarke
The estimated 10-year cumulative incidence of PCSM was 1.2% for those who did not experience biochemical recurrence within 5 years of radiotherapy vs 29.0% among those who did.
© 2024 MJH Life Sciences

All rights reserved.